Roessler, Martin
Schmitt, Jochen
Bobeth, Christoph
Gerken, Michael
Kleihues-van Tol, Kees
Reissfelder, Christoph
Rau, Bettina M.
Distler, Marius
Piso, Pompiliu
Günster, Christian
Klinkhammer-Schalke, Monika
Schoffer, Olaf
Bierbaum, Veronika
Funding for this research was provided by:
Technische Universität Dresden
Article History
Received: 29 November 2021
Accepted: 31 May 2022
First Online: 7 June 2022
Declarations
:
: The WiZen study was approved by the ethics committee of the TU Dresden (reference number: EK95022019). Since the analysis relies on pseudonymized, secondary data, individual consent to participate is not required as confirmed by the ethics committee of the TU Dresden (reference number: EK95022019). The study adheres to all relevant ethical standards and guidelines, including the Declaration of Helsinki, the Memorandum on the Assurance of Good Scientific Practice of the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG), the Memorandum III “Methoden für die Versorgungsforschung” of the Deutsches Netzwerk Versorgungsforschung and the guideline “Good practice secondary data analysis” (GPS) of the German Society for Epidemiology (Deutsche Gesellschaft für Epidemiologie, DGEpi).
: Not applicable.
: MR, JS, CB, OS, and VB work at a university hospital with certified cancer centers. In addition, they received funding from the Innovation Committee of the Federal Joint Committee during the conduct of the study. Unrelated to this study, JS received institutional funding for investigator-initiated research from Sanofi, Pfizer, Novartis, ALK, and acted as a payed consultant for Sanofi, Novartis, ALK and Lilly. OS is a member of the certification commission “Skin Cancer Centers” of the German Cancer Society. The other authors declare that they have no conflict of interest.